WE ARE RARE

Fulcrum is a great place to have a career. Why? Because we have the FULcrew! Our people make us great. At Fulcrum, you can count on finding coworkers who are passionate about their work. Our patient-centered, inclusive, and connected culture enables us to actively listen to the needs of the rare disease community as we lead our science. This makes us and our work rare!

View our open roles

OUR VALUES:

Passionate.

We show up every day with commitment, purpose, and dedication to patients, the business, and each other.

Transformative.

We are scientific leaders focused on creating therapies that transform the lives of patients and caregivers.

Inclusive.

We are committed to a diverse, welcoming, and unique culture that embraces and celebrates everyone. We strive to be as diverse as the community we serve.

Patient-Centered.

We actively listen to the needs of patients, caregivers, and our community as we lead our science. Patients and the advocacy community are the foundation of everything we do.

Connected.

We invest in our people so we can learn, innovate, and grow together. Empowerment and camaraderie are pivotal to our progress.

Make your career a career with impact.

See our available roles below or connect with us at [email protected]

Join the FULcrew

Voices of Fulcrum

Meet the FULcrew and hear our stories.

Are you looking for consistency, commitment, and passion in your career? Join us.

There is always hope for change when people are committed to moving forward together every day, without exception. We call this steadfast commitment our "20 Mile March," inspired by Jim Collins' book Good to Great. At Fulcrum, we pledge to show up passionately every day, dedicated to our work and each other, no matter the challenges we face.

Explore our job openings:

Topline data results from the Phase 3 REACH trial of losmapimod for patients living with Facioscapulohumeral Muscular Dystrophy (FSHD) did not achieve its primary endpoint of change from baseline in reachable workspace.

Read the full press release here: https://ir.fulcrumtx.com/news-releases/news-release-details/fulcrum-therapeutics-announces-topline-results-phase-3-reach

Open
Topline data results from the Phase 3 REACH trial of losmapimod for patients living with Facioscapulohumeral Muscular Dystrophy (FSHD) did not achieve its primary endpoint of change from baseline in reachable workspace. Read the full press release here: https://ir.fulcrumtx.com/news-releases/news-release-details/fulcrum-therapeutics-announces-topline-results-phase-3-reach

Kathleen shares why having a manager who genuinely cares about her whole self—both personally and professionally—makes all the difference at Fulcrum.

#culture #FULcrew

Open
Kathleen shares why having a manager who genuinely cares about her whole self—both personally and professionally—makes all the difference at Fulcrum. #culture #FULcrew

Get connected with the FULcrew and work alongside us to transform the lives of those living with rare diseases.

Learn more about us and apply for our open roles at fulcrumtx.com/careers.

#careers #biotechnology

Open
Get connected with the FULcrew and work alongside us to transform the lives of those living with rare diseases. Learn more about us and apply for our open roles at fulcrumtx.com/careers. #careers #biotechnology

Fulcrum’s Mel Hayes recently joined the @SCDAI’s 22nd Annual Golf Outing. This event brought together passionate SCD advocates and community leaders to raise funds for sickle cell initiatives. Events like these help increase access to resources and support for those living with SCD, making a lasting impact on the community.

Pictured: Mel Hayes, Earla Jones, Reginald Hart, Jr. CFO, SCDAA National, and Talana Hughes

Open
Fulcrum’s Mel Hayes recently joined the @SCDAI’s 22nd Annual Golf Outing. This event brought together passionate SCD advocates and community leaders to raise funds for sickle cell initiatives. Events like these help increase access to resources and support for those living with SCD, making a lasting impact on the community. Pictured: Mel Hayes, Earla Jones, Reginald Hart, Jr. CFO, SCDAA National, and Talana Hughes

Get insights from Genevieve, a valued member of our Discovery Team, as she shares about the significance of working at Fulcrum and what sets us apart, making both our team and our work truly rare.

#WeAreRare

Open
Get insights from Genevieve, a valued member of our Discovery Team, as she shares about the significance of working at Fulcrum and what sets us apart, making both our team and our work truly rare. #WeAreRare

#GreatNews: We’re thrilled to welcome two incredible leaders to the Fulcrum team!

Isabel Kalofonos joins us as our Chief Commercial Officer, and Heather Faulds steps in as our Chief Regulatory Affairs and Quality Assurance Officer.

Welcome, Isabel and Heather!

#Leadership #TeamGrowth #Fulcrum

Open
#GreatNews: We’re thrilled to welcome two incredible leaders to the Fulcrum team! Isabel Kalofonos joins us as our Chief Commercial Officer, and Heather Faulds steps in as our Chief Regulatory Affairs and Quality Assurance Officer. Welcome, Isabel and Heather! #Leadership #TeamGrowth #Fulcrum

Discover the values and background that inspired Suchi from our Discovery Team to join our DEIB Taskforce at Fulcrum.

#DEIB #Culture

Open
Discover the values and background that inspired Suchi from our Discovery Team to join our DEIB Taskforce at Fulcrum. #DEIB #Culture

Darrell explains why his meaningful interactions with patients over the years have shaped his career.

#PatientCentered

Open
Darrell explains why his meaningful interactions with patients over the years have shaped his career. #PatientCentered

Fulcrum Celebrates Sickle Cell Disease Advocate Kadeem Gayle for completing his Doctorate in Medical Humanities.

As students across the country gear up for a new semester to begin, we spoke with SCD Advocate Kadeem Gayle, who recently completed his Doctorate in Medical Humanities (DMH).

This milestone underscores his dedication and resilience in the face of the challenges of living with a rare disease.

Kadeem advises fellow students with rare diseases, particularly those starting out in a new program, to communicate openly about accommodations with professors and advisors and not to be afraid to request part-time study if needed to balance health and academic journeys.

Kadeem’s degree from Drew University, integrated bioethics, narrative medicine, and the human experience. His research focused on the history, origin, and bioethics of sickle cell disease, and has resulted in a compelling anthology of patient stories. Throughout his program, he faced setbacks and physical challenges head on, and his determination never wavered.

Now, with his DMH, Kadeem plans to contribute to the literature, conduct further research, and potentially establish a sickle cell organization. His focus on the patient experience of pain aims to transform how healthcare workers perceive and treat sickle cell disease.

Kadeem’s story is a powerful reminder of what can be achieved with perseverance, dedication, and resilience.

Good luck to all in this coming semester, and congratulations on all of your accomplishments, Dr. Gayle!

Open
Fulcrum Celebrates Sickle Cell Disease Advocate Kadeem Gayle for completing his Doctorate in Medical Humanities. As students across the country gear up for a new semester to begin, we spoke with SCD Advocate Kadeem Gayle, who recently completed his Doctorate in Medical Humanities (DMH). This milestone underscores his dedication and resilience in the face of the challenges of living with a rare disease. Kadeem advises fellow students with rare diseases, particularly those starting out in a new program, to communicate openly about accommodations with professors and advisors and not to be afraid to request part-time study if needed to balance health and academic journeys. Kadeem’s degree from Drew University, integrated bioethics, narrative medicine, and the human experience. His research focused on the history, origin, and bioethics of sickle cell disease, and has resulted in a compelling anthology of patient stories. Throughout his program, he faced setbacks and physical challenges head on, and his determination never wavered. Now, with his DMH, Kadeem plans to contribute to the literature, conduct further research, and potentially establish a sickle cell organization. His focus on the patient experience of pain aims to transform how healthcare workers perceive and treat sickle cell disease. Kadeem’s story is a powerful reminder of what can be achieved with perseverance, dedication, and resilience. Good luck to all in this coming semester, and congratulations on all of your accomplishments, Dr. Gayle!

At Fulcrum, it is always a privilege to meet the people we serve. Our recent All-Hands meeting offered one of those opportunities with FSHD patient advocate Bill Sarraille.

Bill is a nationally recognized healthcare policy expert and a true inspiration to all of us at Fulcrum.
Bill was diagnosed with muscular dystrophy in his third year of law school. At the time, his doctor wasn’t sure whether it was FSHD or limb girdle, but the doctor was sure that there would not be a treatment available in Bill’s lifetime.

So Bill set his diagnosis aside and put all of his energy into his work—healthcare law. Being diagnosed with a rare disease himself gave Bill a passion for helping patients with other rare diseases secure access to treatments, but that didn’t translate into a focus on FSHD.

Late in his career, though, things started to change. Some of Bill’s associates were rare disease patients themselves, and they were much more open about their conditions.

Learning about the work that companies like Fulcrum were doing to potentially bring treatments to market, and the FSHD Society’s work to help build an FSHD research “ecosystem,” Bill was motivated to turn his healthcare expertise towards the disease that his family has struggled with for five generations.

In his 30+ years practicing law, Bill helped numerous rare disease patient groups, drug developers, and others—shepherding rare disease treatments through the coverage and reimbursement pathway.

Though Bill is now retired from his law practice, he is now working in a number of roles, including helping the FSHD Society, as a board member, to support the efforts of research leaders.

Bill has achieved so much while living with FSHD—balancing a demanding career while navigating health challenges, all while working tirelessly to improve the lives of rare disease patients.

Thank you, Bill, for sharing your story with us.

Pictured: Alex Sapir, Bill Sarraille

Open
At Fulcrum, it is always a privilege to meet the people we serve. Our recent All-Hands meeting offered one of those opportunities with FSHD patient advocate Bill Sarraille. Bill is a nationally recognized healthcare policy expert and a true inspiration to all of us at Fulcrum. Bill was diagnosed with muscular dystrophy in his third year of law school. At the time, his doctor wasn’t sure whether it was FSHD or limb girdle, but the doctor was sure that there would not be a treatment available in Bill’s lifetime. So Bill set his diagnosis aside and put all of his energy into his work—healthcare law. Being diagnosed with a rare disease himself gave Bill a passion for helping patients with other rare diseases secure access to treatments, but that didn’t translate into a focus on FSHD. Late in his career, though, things started to change. Some of Bill’s associates were rare disease patients themselves, and they were much more open about their conditions. Learning about the work that companies like Fulcrum were doing to potentially bring treatments to market, and the FSHD Society’s work to help build an FSHD research “ecosystem,” Bill was motivated to turn his healthcare expertise towards the disease that his family has struggled with for five generations. In his 30+ years practicing law, Bill helped numerous rare disease patient groups, drug developers, and others—shepherding rare disease treatments through the coverage and reimbursement pathway. Though Bill is now retired from his law practice, he is now working in a number of roles, including helping the FSHD Society, as a board member, to support the efforts of research leaders. Bill has achieved so much while living with FSHD—balancing a demanding career while navigating health challenges, all while working tirelessly to improve the lives of rare disease patients. Thank you, Bill, for sharing your story with us. Pictured: Alex Sapir, Bill Sarraille